Gusacitinib is a dual inhibitor of JAKs (IC50s = 46, 4, and 11 nM for JAK1-3, respectively) and Syk family kinases (IC50s = 5 and 8 nM for SyK and TYK2, respectively).1
1.Bissonnette, R., Maari, C., Forman, S., et al.The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: Results from a randomized double-blind placebo-controlled studyBr. J. Dermatol.181(4)733-742(2019)